Canadian Co-infection Cohort
The Canadian Co-infection Cohort Study follows a group of HIV and hepatitis C (HCV) co-infected patients from 16 centers across Canada.
The cohort was established in 2002 at three University centers in Quebec with infrastructure funding from the Fonds de la recherche en santé du Québec (FRSQ). In 2005 we received funding from the Canadian Institutes of Health Research (CIHR) to expand to an additional 13 sites across Canada.
The primary objective of this study is to determine the effect of highly active antiretroviral therapy (HAART) on liver disease progression in HIV-HCV co-infection. We have now enrolled 950 participants across Canada; a unique cohort similar to no other cohorts worldwide.
Participants are not required to take any special medications or change any of their behaviours, but are asked to complete a questionnaire every six months for five years. The questionnaires collect detailed information on demographics, drug and alcohol use, risk behaviours, smoking habits, quality of life measures as well as HIV and HCV treatment information. Blood samples are also collected and stored to perform viral, pathogenic and immunologic studies.
A Prospective Clinical Cohort of HIV and Hepatitis C Co-infected Patients
Canadian Co-infection Cohort @ 2009. All rights reserved. | Web design by Jen Burkholder